Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients | Zendy

Stephen C. Piscitelli | Zendy; William D. Figg | Zendy; Beatrice H. Hahn | Zendy; Gerald D. Kelly | Zendy; Steve D. Thomas | Zendy; Robert Walker | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients

Author(s) -

Stephen C. Piscitelli,

William D. Figg,

Beatrice H. Hahn,

Gerald D. Kelly,

Steve D. Thomas,

Robert Walker

Publication year - 1997

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.41.12.2797

Subject(s) - pharmacokinetics , thalidomide , dosing , adverse effect , medicine , pharmacology , human immunodeficiency virus (hiv) , sida , viral disease , gastroenterology , virology , multiple myeloma

The pharmacokinetics of thalidomide in nine human immunodeficiency virus-infected patients were studied. Single doses of thalidomide were well absorbed, with mean peak concentrations (+/- standard deviations) of 1.17 +/- 0.21 and 3.47 +/- 1.14 microg/ml in the 100- and 300-mg dosing groups, respectively, and the mean elimination half-life was approximately 6 h. Adverse effects were mild, with drowsiness being reported for seven of nine patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research